• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Parents file lawsuit against Mylan over EpiPen ‘price-gouging’

September 7, 2016 By Sarah Faulkner

Mylan's EpiPenA parent in Ohio reportedly leveled a class-action lawsuit against EpiPen maker Mylan (NSDQ:MYL) over the nearly 500% increase in the cost of the epinephrine injector since Mylan acquired the device in 2007.

The suit, filed yesterday in Hamilton County Common Pleas Court, seeks an unspecified amount of damages for its 25 plaintiffs, according to Cincinnati.com. Plaintiffs’ attorney Carl Lewis said the roster of plaintiffs could increase significantly, according to the website.

Lead plaintiff Linda Bates is a Connecticut resident whose 15-year-old son carries an EpiPen in case of a peanut allergy attack. The lawsuit alleges that the price for a pair of EpiPens surged from $50 a year to $600.

Mylan violated Ohio’s Consumer Sales Practices Act, which prohibits a supplier from committing “an unconscionable act or practice in connection with a consumer transaction,” the suit alleges, according to the site.

“I filed the lawsuit to right an injustice,” Lewis told Cincinnati.com. “The fact is, Mylan Pharmaceuticals – or any company – will not stop unconscionable practices if we as individuals … don’t strike. And I’m striking because I think it’s outrageous.”

The lawsuit calls the company’s actions “immoral” and “nothing more than price-gouging.”

The company defended the price hikes, with CEO Heather Bresch calling the costs justified because of improvements Mylan made to the device. Bresch cited the “complexity and opaqueness of today’s branded pharmaceutical supply chain” as a motivation for companies that raise their prices.

In response to calls from politicians for federal investigations into Mylan’s cost analysis, the company said in late August that it would expand existing patient support programs and develop a cheaper generic that would cost around $300 for a pair of injectors.

When the initial bout of criticism began August 22, MYL shares dropped 10%; the stock was trading at $40.45 per share today in early trading, up 0.12%.

Filed Under: Drug-Device Combinations, Legal News Tagged With: Mylan

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS